Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Re: Effect of Aflibercept on Refractory Macular Edema Associated with Central Retinal Vein Occlusion.

Chiang A, Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander JF.

Can J Ophthalmol. 2017 Feb;52(1):137-138. doi: 10.1016/j.jcjo.2016.12.001. No abstract available.

PMID:
28237140
2.

Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.

Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J, Chiang A.

Can J Ophthalmol. 2016 Oct;51(5):342-347. doi: 10.1016/j.jcjo.2016.02.001. Epub 2016 Sep 3.

PMID:
27769324
3.

ANALYSIS OF PARS PLANA VITRECTOMY INCISIONS USING LIVE BACTERIA.

Cohen MN, Houston SK 3rd, Roberts AL, Eagle RC Jr, Gupta OP.

Retina. 2017 Jun;37(6):1152-1159. doi: 10.1097/IAE.0000000000001319.

PMID:
27668930
4.

INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).

Houston SK 3rd, Rayess N, Cohen MN, Ho AC, Regillo CD.

Retina. 2015 Sep;35(9):1757-64. doi: 10.1097/IAE.0000000000000663.

PMID:
26110596
5.

Self-induced Orbital Compression Injury: Saturday Night Retinopathy.

Williams AL, Greven M, Houston SK, Mehta S.

JAMA Ophthalmol. 2015 Aug;133(8):963-5. doi: 10.1001/jamaophthalmol.2015.1114. No abstract available.

PMID:
25996124
6.

Bilateral Straatsma syndrome with nystagmus.

Juhn AT, Houston SK 3rd, Mehta S.

Retin Cases Brief Rep. 2015 Summer;9(3):198-200. doi: 10.1097/ICB.0000000000000137.

PMID:
25876184
7.

Spectrum of Retinal Vascular Diseases Associated With Paracentral Acute Middle Maculopathy.

Chen X, Rahimy E, Sergott RC, Nunes RP, Souza EC, Choudhry N, Cutler NE, Houston SK, Munk MR, Fawzi AA, Mehta S, Hubschman JP, Ho AC, Sarraf D.

Am J Ophthalmol. 2015 Jul;160(1):26-34.e1. doi: 10.1016/j.ajo.2015.04.004. Epub 2015 Apr 4.

PMID:
25849522
8.

Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.

Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C.

Am J Ophthalmol. 2015 May;159(5):861-7.e2. doi: 10.1016/j.ajo.2015.01.034. Epub 2015 Feb 4.

PMID:
25660387
9.

Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.

Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD.

Am J Ophthalmol. 2015 Jan;159(1):3-8.e1. doi: 10.1016/j.ajo.2014.09.011. Epub 2014 Sep 8.

PMID:
25217859
10.

Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice.

Shah NV, Pham DG, Murray TG, Decatur C, Hernandez E, Shah NN, Cavalcante M, Houston SK.

J Ophthalmol. 2014;2014:829879. doi: 10.1155/2014/829879. Epub 2014 Mar 10.

11.

Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma.

Shah NV, Houston SK, Markoe A, Murray TG.

Clin Ophthalmol. 2013;7:1877-82. doi: 10.2147/OPTH.S47684. Epub 2013 Sep 20.

12.

Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma.

Lonngi M, Houston SK, Murray TG, Sisk RA, Decatur CL, Cavalcante M, Markoe AM.

Clin Ophthalmol. 2013;7:427-35. doi: 10.2147/OPTH.S36413. Epub 2013 Feb 27.

13.

Models and discovery strategies for new therapies of retinoblastoma.

Houston SK, Lampidis TJ, Murray TG.

Expert Opin Drug Discov. 2013 Apr;8(4):383-94. doi: 10.1517/17460441.2013.772975. Epub 2013 Feb 22. Review.

PMID:
23427911
14.

Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, Murray TG.

Clin Ophthalmol. 2013;7:193-8. doi: 10.2147/OPTH.S37938. Epub 2013 Jan 22.

15.

Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG.

Clin Ophthalmol. 2012;6:1739-48. doi: 10.2147/OPTH.S34949. Epub 2012 Oct 29.

16.

Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification.

Parke DW 3rd, Sisk RA, Houston SK, Murray TG.

Clin Ophthalmol. 2012;6:925-31. doi: 10.2147/OPTH.S32934. Epub 2012 Jun 18.

17.

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ.

Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29.

18.

Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review.

Shah NV, Houston SK, Murray TG, Markoe AM.

Clin Ophthalmol. 2012;6:447-52. doi: 10.2147/OPTH.S30307. Epub 2012 Mar 20.

19.

Lasers for the treatment of intraocular tumors.

Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG.

Lasers Med Sci. 2013 May;28(3):1025-34. Review.

PMID:
22302638
20.

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T.

Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.

Supplemental Content

Loading ...
Support Center